Skip to content
Screener

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
-$2.04M+98.0%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.39M+253%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$52.8M-3,386%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$394.19M+13,285%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$4.65M-166%

Other financials

Income statement

See full
Revenue$92.1M+28.7%
Gross profit$79.6M+33.4%
Operating income$5.2M+15.4%
Net income-$31.1M-1,513%
EPS (diluted)-$0.18-1,700%

Balance sheet

See full
Cash & equivalents$121.7M+105%
Total debt$289.4M+12.5%
Total equity-$9.7M+49.6%
Total assets$411.9M+23.1%

Cash flow

See full
Operating cash flow$8.3M+4,440%
CapEx$131.0K
Free cash flow-$29.1M

Valuation

See full
Market cap$1.46B+25.3%
Enterprise value$1.62B+19.4%
P/S4.3×-0.4×

Profitability

See full
Gross margin86.6%+4.3pp
Operating margin10.9%+8.4pp
Net margin-5.1%-1.9pp

Returns & leverage

See full
Return on equity-209.8%
Debt / equity19.9×
Current ratio1.4×-0.5×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001867096-26-000030
Line itemThree Months Ended March 31, 20262025
Proceeds from exercise of stock options8474,861
Proceeds from issuance of common shares in settlement of warrants7,333
Repurchase of common stock withheld for taxes(17,017)(7,998)
Net cash used in financing activities(8,837)(3,137)
Net increase (decrease) in cash, cash equivalents, and restricted cash708(13,181)
Cash, cash equivalents and restricted cash, beginning of year115,06375,744
Cash, cash equivalents and restricted cash, end of quarter$115,771$62,563
20262025

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Xeris Biopharma Holdings, Inc.'s financing cash flow?
Xeris Biopharma Holdings, Inc. (XERS) reported financing cash flow of -$8.84M in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s financing cash flow changed year-over-year?
Xeris Biopharma Holdings, Inc.'s financing cash flow decreased by 181.7% year-over-year, from -$3.14M to -$8.84M.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s financing cash flow?
Over 2 years (2021 to 2024), Xeris Biopharma Holdings, Inc.'s financing cash flow has grown at a 15.3% compound annual growth rate (CAGR), from $27.25M to $36.25M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Xeris Biopharma Holdings, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude